Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

NCT06329947 is registered in ClinicalTrials.gov with Rui-hua Xu, MD, PhD as lead sponsor.

NCT NCT06329947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06329947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
Lead sponsor
Rui-hua Xu, MD, PhD
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 22, 2024
Completion date
September 30, 2026
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer